Egle Therapeutics
Modulating T-regulatory cells to balance immunity
France
45 employees
Grant
Total: $49.30M
Biotechnology, Health Care +1
General Information
Get notified when Egle Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Egle Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biotechnology
About Egle Therapeutics
Taxonomy: immunomodulation, T-regulatory cells, immunotherapy, oncology, autoimmune diseases, immune suppressor, regulatory T-cells, Paris, emerging, cancer treatment, immune system, therapeutic development
Services & Products
Target Customers
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | •••••• | 1 | •••• •••• | 17 Mar 2025 |
| Series A | •••••• | 6 |
|
22 Oct 2021 |
Egle Therapeutics Alternatives & Competitors
Pioneering breakthrough treatments for autoimmune and inflammatory diseases with a focus on enhancin...
Innovative therapies for autoimmune diseases. Global pioneer in cellular therapies based on TREGS c...
Creating a future where inflammatory disorders are curable
vs
Mozart Therapeutics, Inc.
FAQ About Egle Therapeutics
Don't just browse. Track.
Signal Tracker monitors Egle Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.